Sharath Hegde, Vice President at Theravance to Give Featured Presentation at GTCbio’s Bugs & Drugs Conference on September 22-23, 2008 in San Diego, CA
Monrovia, CA, August 21, 2008 --(PR.com)-- Sharath Hegde, Vice President of Pharmacology at Theravance, Inc. in South San Francisco, CA will speak on “Telavancin: A Novel Lipoglycopeptide Gram-Positive Antibiotic” at GTCbio’s Bugs & Drug Conference on September 22-23, 2008 at the DoubleTree Club Hotel in San Diego, CA.
Telavancin (TLV) is an investigational lipoglycopeptide antibiotic that has broad-spectrum activity against Gram-positive bacteria, including MRSA and strains with reduced susceptibility to vancomycin. Telavancin's multifunctional mechanism of action, including inhibition of peptidoglycan synthesis and disruption of membrane potential, account for this enhanced activity as well as rapid bactericidal properties. TLV is a once-daily dosed antibiotic, and its pharmacodynamically-linked parameter is AUC/MIC. Several preclinical studies have demonstrated that Telavancin is efficacious in animal models of soft-tissue (thigh) and deep-seated (endocarditis, bacteremia, pneumonia, meningitis and osteomyeletis) infections. Telavancin has been shown to be efficacious in Phase 3 clinical studies in patients with complicated skin and skin-structure infections (cSSSI) and hospital acquired pneumonia (HAP). Telavancin appears to be a promising agent for the treatment of serious infections caused by Gram-positive pathogens, including drug-resistant pathogens.
GTCbio’s Bugs & Drugs conference brings together top industry leaders including directors, vice presidents, heads, managers, supervisors, from all over the world to collaborate and discuss novel approaches to problematic pathogens for community-acquired Infections and hospital-acquired infections, contingency plans for biological weapons and disease outbreaks, the changing landscape of antibacterial development - politics vs. commerce, and the future of infectious disease therapeutics. For more information including a detailed agenda, exhibitor opportunities and registration information visit http://gtcbio.com/conferenceDetails.aspx?id=129.
About GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCbio 434 W. Foothill Blvd. Monrovia, CA 91016 Tel: (626) 256-6405 fax: (626) 256-6460 email: nina.tran@gtcbio.com
###
Telavancin (TLV) is an investigational lipoglycopeptide antibiotic that has broad-spectrum activity against Gram-positive bacteria, including MRSA and strains with reduced susceptibility to vancomycin. Telavancin's multifunctional mechanism of action, including inhibition of peptidoglycan synthesis and disruption of membrane potential, account for this enhanced activity as well as rapid bactericidal properties. TLV is a once-daily dosed antibiotic, and its pharmacodynamically-linked parameter is AUC/MIC. Several preclinical studies have demonstrated that Telavancin is efficacious in animal models of soft-tissue (thigh) and deep-seated (endocarditis, bacteremia, pneumonia, meningitis and osteomyeletis) infections. Telavancin has been shown to be efficacious in Phase 3 clinical studies in patients with complicated skin and skin-structure infections (cSSSI) and hospital acquired pneumonia (HAP). Telavancin appears to be a promising agent for the treatment of serious infections caused by Gram-positive pathogens, including drug-resistant pathogens.
GTCbio’s Bugs & Drugs conference brings together top industry leaders including directors, vice presidents, heads, managers, supervisors, from all over the world to collaborate and discuss novel approaches to problematic pathogens for community-acquired Infections and hospital-acquired infections, contingency plans for biological weapons and disease outbreaks, the changing landscape of antibacterial development - politics vs. commerce, and the future of infectious disease therapeutics. For more information including a detailed agenda, exhibitor opportunities and registration information visit http://gtcbio.com/conferenceDetails.aspx?id=129.
About GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCbio 434 W. Foothill Blvd. Monrovia, CA 91016 Tel: (626) 256-6405 fax: (626) 256-6460 email: nina.tran@gtcbio.com
###
Contact
GTCbio
Rania Hafez
626-256-6405
http://www.gtcbio.com
Rania Hafez
626-256-6405
http://www.gtcbio.com
Contact
Categories